Screener
Regeneron Pharmaceuticals REGN Business Segments
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| Revenue by Product | ||||||
| Evkeeza | $53.3M+29.4% | —— | —— | —— | $41.2M— | |
| EYLEA HD | $596.3M+51.7% | —— | —— | —— | $393.2M— | |
| EYLEA | $412.2M-45.4% | —— | —— | —— | $754.3M— | |
| Libtayo | $489.4M+30.0% | $438.2M+53.7% | $425.4M+15.9% | $365.2M+26.5% | $376.5M+26.6% | |
| Lynozyfic | $16.5M— | $11.2M— | —— | —— | $0— | |
| Other products | $0— | $31.3M— | $9.3M— | $800K— | $0— | |
| Praluent | $74.7M+13.5% | —— | —— | —— | $65.8M— |
FAQ
- How does Regeneron Pharmaceuticals break its business down?
- Regeneron Pharmaceuticals (REGN) reports revenue by product across 7 parts — Evkeeza, EYLEA HD, EYLEA, Libtayo and Lynozyfic. Each is extracted from the segment footnotes and tracked over time.
- Where does Regeneron Pharmaceuticals's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Regeneron Pharmaceuticals's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
